Year: 2015
Type: review
Abstract: Genetic studies in the 1980s and 1990s led to landmark discoveries that sarcomere mutations cause both hypertrophic and dilated cardiomyopathies. Sarcomere mutations also likely play a role in more complex phenotypes and overlap cardiomyopathies with features of hypertrophy, dilation, diastolic abnormalities, and non-compaction. Identification of the genetic cause of these important conditions provides unique opportunities to interrogate and characterize disease pathogenesis and pathophysiology, starting from the molecular level and expanding from there. With such insights, there is potential for clinical translation that may transform management of patients and families with inherited cardiomyopathies. If key pathways for disease development can be identified, they could potentially serve as targets for novel disease-modifying or disease-preventing therapies. By utilizing gene-based diagnostic testing, we can identify at-risk individuals prior to the onset of clinical disease, allowing for disease-modifying therapy to be initiated early in life, at a time that such treatment may be most successful. In this section, we review the current application of genetics in clinical management, focusing on hypertrophic cardiomyopathy as a paradigm; discuss state-of-the-art genetic testing technology; review emerging knowledge of gene expression in sarcomeric cardiomyopathies; and discuss both the prospects, as well as the challenges, of bringing genetics to medicine.
Source: Cardiovascular Research
DOI: 10.1093/cvr/cvv025
Institutions: Brigham and Women's Hospital, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hôpital Ambroise-Paré, Fondation pour l’innovation en Cadiométabolisme et Nutrition, Azienda Ospedaliero-Universitaria Careggi, Amsterdam UMC Location University of Amsterdam, University of Amsterdam
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,329
OpenAlex ID: W2170147086
